Drug Development
With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, “Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets said Tuesday.
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
The FDA said that arimoclomol, which has been studied and submitted for NPC indication, needs further data to support its use in this rare, progressive genetic disorder.
New data shows Zolgensma, Novartis’ gene therapy for spinal muscular atrophy, has the potential to be used presymptomatically in juveniles.
Three other drug contenders that work similarly to Biogen’s drug are currently in clinical trials and expecting data relatively soon.
Eisai believes this is a potential-best in class FRα ADC that has shown single agent activity in patients with advanced solid tumors, including endometrial, ovarian, lung and breast cancers.
Findings from the study suggest the oral JAK inhibitor tofacitinib could be a potential contender in the race to identify benefits for COVID-19 in already approved therapies.
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
Scientists call for more investigation into the origin of the virus, particularly in China, but China now wants to include the U.S. in the probe.
XTX101 is a tumor-selective anti-CTLA-4 monoclonal antibody designed to improve upon the safety of current therapies in the same class.
The new findings likely throw a wrench in the company’s plans to deliver millions of much-needed vaccine doses to the European Union soon.
The FDA granted it to Lu-PSMA-617, an investigational radioligand therapy to treat metastatic castration-resistant prostate cancer.